Benjamin Hohl Sells 10,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $30.68 on Thursday. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.93. The stock has a 50 day moving average price of $26.19 and a two-hundred day moving average price of $22.08. The company has a market capitalization of $1.83 billion, a P/E ratio of -16.49 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC purchased a new position in Enliven Therapeutics during the 2nd quarter valued at $8,024,000. Candriam S.C.A. lifted its position in shares of Enliven Therapeutics by 46.3% in the 3rd quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock worth $12,473,000 after purchasing an additional 192,702 shares during the period. Geode Capital Management LLC boosted its stake in shares of Enliven Therapeutics by 7.8% during the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after purchasing an additional 63,580 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Enliven Therapeutics by 2,029.3% during the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after purchasing an additional 410,034 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Enliven Therapeutics by 177.4% during the second quarter. SG Americas Securities LLC now owns 36,373 shares of the company’s stock valued at $730,000 after buying an additional 23,261 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ELVN. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.